31992-43-5

Basic information

• Product Name: 1-(3-AMINOPHENYL)PYRROLIDIN-2-ONE
• Synonyms: 1-(3-aminophenyl)pyrrolidin-2-one(SALTDATA: FREE);1-(3-aminophenyl)-2-pyrrolidone
• CAS NO: 31992-43-5
• Molecular Formula: C₁₀H₁₂N₂O
• Molecular Weight: 176.22
• Mol File: 31992-43-5.mol

Chemical Properties

• Melting Point: 105-107 °C(Solv: benzene (71-43-2))
• Boiling Point: 464.5°C at 760 mmHg
• Flash Point: 234.7°C
• Appearance: /
• Density: 1.234g/cm³
• Vapor Pressure: 8.34E-09mmHg at 25°C
• Refractive Index: 1.63
• PKA: 4.22±0.10(Predicted)
• CAS DataBase Reference: 1-(3-AMINOPHENYL)PYRROLIDIN-2-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-AMINOPHENYL)PYRROLIDIN-2-ONE(31992-43-5)
• EPA Substance Registry System: 1-(3-AMINOPHENYL)PYRROLIDIN-2-ONE(31992-43-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 31992-43-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(3-Aminophenyl)pyrrolidin-2-one is used as a building block for the synthesis of various biologically active compounds due to its versatile chemical structure and potential to be modified for specific therapeutic effects.
Used in Antidepressant and Anxiolytic Development:
1-(3-Aminophenyl)pyrrolidin-2-one is used as a potential antidepressant and anxiolytic agent, leveraging its capacity to modulate neurotransmitter systems involved in mood regulation and anxiety disorders.
Used in Pain and Inflammation Treatment:
1-(3-Aminophenyl)pyrrolidin-2-one is used as an inhibitor of the enzyme fatty acid amide hydrolase (FAAH), a target for treating pain and inflammation by affecting the endocannabinoid system, which plays a role in pain perception and modulation.
Used in Medicinal Chemistry Research and Development:
1-(3-Aminophenyl)pyrrolidin-2-one is utilized in the field of medicinal chemistry for further research and development, given its potential to contribute to the discovery of new drugs and therapeutic agents for various medical conditions.

InChI:InChI=1/C10H12N2O/c11-8-3-1-4-9(7-8)12-6-2-5-10(12)13/h1,3-4,7H,2,5-6,11H2

Upstream product

• 96-48-0 4-butanolide 
• 108-45-2 m-phenylenediamine 
• 61372-79-0 1-(3-nitrophenyl)-2-oxotetrahydropyrrole 
• 99-09-2 3-nitro-aniline 
• 585-79-5 m-nitrobromobenzene 

Downstream Products

• 329280-75-3 1-[3-(5-bromo-3-nitropyridin-2-ylamino)phenyl]pyrrolidin-2-one 
• 922950-58-1 N-(3-(2-oxopyrrolidin-1-yl)phenyl)pivalamide 
• 330657-69-7 N-(3-(2-oxopyrrolidin-1-yl)phenyl)benzamide 
• 922886-66-6 N-(3-(2-oxopyrrolidin-1-yl)phenyl)butyramide 
• 1014949-96-2 N-(3-(2-oxopyrrolidin-1-yl)phenyl)cinnamamide 
• 922926-09-8 N-(3-(2-oxopyrrolidin-1-yl)phenyl)cyclohexanecarboxamide 
• 1257516-09-8 (E)-tert-butyl (tert-butoxycarbonylamino)(3-(2-oxopyrrolidin-1-yl)phenylamino)methylenecarbamate 
• 1215126-62-7 1-(3-{[4-chloro-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)pyrrolidin-2-one 
• 1215125-42-0 1-[3-({5-(Trifluoromethyl)-4-[(1,1,1-trifluoropropan-2-yl)amino]pyrimidin-2-yl}amino)phenyl]-pyrrolidin-2-one 
• 1443438-15-0 C₂₅H₂₃F₆N₃O₃ 
• 1401731-36-9 1-(3-((6-(3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)amino)phenyl)pyrrolidin-2-one 
• 1401732-44-2 1-(3-((6-(1-(4-methoxybenzyl)-3-methyl-1H-pyrazolo[3,4-b]pyridin-5-yl)pyrazin-2-yl)amino)phenyl)pyrrolidin-2-one 
• 1401732-43-1 1-(3-((6-chloropyrazin-2-yl)amino)phenyl)pyrrolidin-2-one 
• 1233206-32-0 3-[6-(3-(2-oxopyrrolidin-1-yl)phenylamino)pyridin-2-yl]pyrazolo[1,5-a]pyridine 

Relevant articles and documents

Novel tertiary sulfonamides as potent anti-cancer agents

For adult women in the United States, breast cancer is the most prevalent form of cancer. Compounds that target dysregulated signal transduction can be efficacious anti-cancer therapies. A prominent signaling pathway frequently dysregulated in breast canc

CONDENSED HETEROCYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I) wherein R1, A, B, D, E, G, Q, Ar, n, m, and p are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

4'-AMINO CYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): formula (I) wherein Cy is selected from formula (Il) and wherein R1, R2, R3, Q, G, Ar, m, n and p are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS

The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazopyridazines inhibit protein kinase activity thereby making them useful as anticancer agents.

3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein Q, R1, R4, m and Ar are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

Copper-catalyzed synthesis of benzoxazoles via a regioselective C-H functionalization/C-O bond formation under an air atmosphere

(Chemical Equation Presented) An efficient method for the synthesis of functionalized benzoxazoles is described that involves a copper(II)-catalyzed regioselective C-H functionalization/C-O bond formation protocol. The use of dichlorobenzene as a solvent at 160°C allows the use of air as the terminal oxidant in the catalytic synthesis of benzoxazoles in a process that has high functional group tolerance. The presence of a directing group at the meta position markedly improves the reaction efficacy and a variety of 7-substituted benzoxazoles are selectively produced under mild reaction conditions. The mechanism of the reaction is also discussed in this report.

IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS

The present invention is directed to 3-phenylimidazol[4,5-b]pyridine derivatives, that are selective ligands for GABAA receptors. These compounds are useful in the treatment and prevention of disorders of the central nervous system, including anxiety and convulsions.